Ablynx replaces chief business officer

Belgian biotech drug developer Ablynx (Euronext Brussels: ABLX) has replaced its chief business officer, appointing Markus Ewert to lead the company’s business development and corporate strategy.

Dr Ewert previously headed up the business development team at the healthcare division of General Electric. He also worked at Novartis (NOVN: VX) in similar roles, and has been chief executive at two smaller biotech companies.

Chief executive Edwin Moses said: "Markus brings extensive experience in leading business development teams and executing licensing deals and acquisitions.”

“Having held senior positions in big pharma as well as in biotech and consultancy firms, he is ideally suited to become part of our executive committee and play an important role in helping Ablynx achieve its business objectives."

Dr Ewert said: “I am very excited to join the Ablynx team and lead their business development and strategy activities. Ablynx's Nanobody platform has been clearly demonstrated to be a very powerful tool in the development of potentially new and important therapeutics.”